Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH

Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH 1INTRODUCTIONPatients with ischemic cardiomyopathy are at risk of scar‐related ventricular arrhythmias. Implanted cardioverter defibrillators (ICDs) reduce mortality by delivering pacing or shock therapies, but these therapies to reduce ventricular arrhythmias may reduce quality of life. The VANISH trial compared strategies of escalated antiarrhythmic drug (AAD) therapy with catheter ablation in patients with ischemic cardiomyopathy and ventricular tachycardia (VT) despite first‐line AAD therapy. It demonstrated a reduction in the composite outcome of death, VT, or appropriate ICD shock in the ablation group. We aimed to compare health‐related quality of life (HRQoL) in patients randomized to escalated therapy and those randomized to ablation in the VANISH trial. We hypothesized that ablation would improve HRQoL by reducing anxiety related to anticipation of arrhythmia symptoms or recurrent ICD shocks.2METHODS2.1VANISH trialThe methods, inclusion and exclusion criteria of the VANISH trial, have been previously published. Briefly, VANISH was a multicenter, randomized trial at 22 ablation centers in Canada, Europe, the United States, and Australia. Eligible patients had a history of myocardial infarction, ICD implant, and recent monomorphic VT treated with amiodarone or a class I or III AAD. Patients were randomized to catheter ablation for VT, or an escalation in AAD therapy. In the escalated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cardiovascular Electrophysiology Wiley

Loading next page...
 
/lp/wiley/quality-of-life-with-ablation-or-medical-therapy-for-ventricular-B6UyF41ME0
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Journal compilation © 2018 Wiley Periodicals, Inc.
ISSN
1045-3873
eISSN
1540-8167
D.O.I.
10.1111/jce.13419
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONPatients with ischemic cardiomyopathy are at risk of scar‐related ventricular arrhythmias. Implanted cardioverter defibrillators (ICDs) reduce mortality by delivering pacing or shock therapies, but these therapies to reduce ventricular arrhythmias may reduce quality of life. The VANISH trial compared strategies of escalated antiarrhythmic drug (AAD) therapy with catheter ablation in patients with ischemic cardiomyopathy and ventricular tachycardia (VT) despite first‐line AAD therapy. It demonstrated a reduction in the composite outcome of death, VT, or appropriate ICD shock in the ablation group. We aimed to compare health‐related quality of life (HRQoL) in patients randomized to escalated therapy and those randomized to ablation in the VANISH trial. We hypothesized that ablation would improve HRQoL by reducing anxiety related to anticipation of arrhythmia symptoms or recurrent ICD shocks.2METHODS2.1VANISH trialThe methods, inclusion and exclusion criteria of the VANISH trial, have been previously published. Briefly, VANISH was a multicenter, randomized trial at 22 ablation centers in Canada, Europe, the United States, and Australia. Eligible patients had a history of myocardial infarction, ICD implant, and recent monomorphic VT treated with amiodarone or a class I or III AAD. Patients were randomized to catheter ablation for VT, or an escalation in AAD therapy. In the escalated

Journal

Journal of Cardiovascular ElectrophysiologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial